M

Mirum Pharmaceuticals

ASBT inhibitors for rare liver diseases

Senior Director - New Product Planning

Corporate StrategyConfirmed live in the last 24 hours
Full-timeFoster City, CA, USA$280k - $315k

About the Job

Requirements

  • At least 10 years of experience in the biotechnology or pharmaceutical industry, including significant experience in New Product Planning, Commercial Strategy, Portfolio Strategy, Business Development, Business Analytics, Marketing, Market Access, or related roles.
  • Strong scientific acumen and ability to understand disease biology, molecular pathways, mechanisms of action, and clinical data and translate them into commercial and development strategy.
  • Experience shaping strategy for pipeline assets, preferably during early- and mid-stage clinical development.
  • Experience evaluating new indications, lifecycle opportunities, new therapeutic areas, and/or external innovation opportunities.
  • Strong experience with commercial forecasting, primary and secondary market research, business cases, and asset valuation.
  • Ability to influence senior leaders and cross-functional teams without direct authority.
  • Ability to communicate complex scientific, clinical, and commercial concepts effectively to scientific experts and senior executives.

Responsibilities

  • Lead commercial assessments of licensing, acquisition, and partnership opportunities, integrating scientific rationale, unmet need, clinical profile, competitive landscape, commercial potential, pricing and market access, and strategic fit.
  • Conduct primary and secondary market research to develop patient-based forecasts, scenario analyses, and risk-adjusted valuations to support investment and transaction decisions.
  • Partner with Business Development, R&D, Finance, and US and Global Commercial throughout opportunity evaluation and diligence.
  • Serve as the commercial strategy lead on cross-functional product teams for pre-Phase 3 pipeline programs before transition.
  • Develop business cases and commercial strategies for pipeline assets, including indication prioritization, Target Product Profiles, patient segmentation, value story, competitive differentiation, market opportunity, and lifecycle planning.
  • Partner with Research, Clinical Development, Market Access, and Medical Affairs to incorporate commercial considerations into development strategy, including patient populations, endpoints, comparators, and real-world and health economic evidence generation.
  • Partner with US and Global Commercial leaders to incorporate perspectives from key markets and ensure effective transition of assets into late-stage commercial planning.
  • Evaluate new therapeutic areas and disease spaces by integrating disease biology, unmet need, competitive dynamics, development feasibility, and commercial potential.
  • Shape portfolio and corporate strategy by identifying growth opportunities, strategic gaps, and priorities for investment and resource allocation.
  • Own commercial assumptions that inform long-range planning for all pre-Phase 3 programs.
  • Monitor scientific, clinical, competitive, regulatory, and market developments and translate them into implications for product and portfolio strategy.

Desired Qualifications

  • A PhD or MD is strongly preferred; other advanced scientific or medical degrees with relevant experience will be considered.
  • Experience in rare disease and/or specialty therapeutics.
  • Experience collaborating with global commercial teams and working across multiple therapeutic areas.
  • Experience supporting licensing, acquisition, or other business development transactions.
  • Experience presenting strategic recommendations to Executive Leadership and governance committees.

About the Company

Mirum Pharmaceuticals

ASBT inhibitors for rare liver diseases

Mirum develops therapies for rare liver diseases, led by LIVMARLI (maralixibat), an oral ASBT inhibitor that reduces bile acid buildup and itching in Alagille syndrome and other cholestatic conditions. It is pursuing LIVMARLI for additional rare diseases such as PFIC and biliary atresia and developing volixibat for primary sclerosing cholangitis and primary biliary cholangitis. The company combines drug development with commercialization in the United States and other major markets, working with physicians, payers, and patient groups to improve access. Its goal is to bring effective therapies to patients with rare liver diseases and build a sustainable commercial presence in key markets.

Company size
501-1,000
Company stage
IPO
Headquarters
Foster City, CA
Founded
2018

Recently Posted Jobs

Explore more opportunities at Mirum Pharmaceuticals

See more jobs